Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

CEO

Michael E. Severino

CEOMichael E. Severino

Employees

835

Employees835

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

835

Employees835

SRPT Key Statistics

Market cap

1.78B

Market cap1.78B

Price-Earnings ratio

-5.70

Price-Earnings ratio-5.70

Dividend yield

—

Dividend yield—

Average volume

2.87M

Average volume2.87M

High today

$17.12

High today$17.12

Low today

$16.37

Low today$16.37

Open price

$16.53

Open price$16.53

Volume

2.74M

Volume2.74M

52 Week high

$24.68

52 Week high$24.68

52 Week low

$14.68

52 Week low$14.68

Stock Snapshot

The current Sarepta Therapeutics(SRPT) stock price is $16.80, with a market capitalization of 1.78B. The stock trades at a price-to-earnings (P/E) ratio of -5.70.

As of 2026-10-14, Sarepta Therapeutics(SRPT) stock has fluctuated between $16.37 and $17.12. The current price stands at $16.80, placing the stock +2.6% above today's low and -1.9% off the high.

The Sarepta Therapeutics(SRPT)'s current trading volume is 2.74M, compared to an average daily volume of 2.87M.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $14.68 at its lowest and $24.68 at its peak.

SRPT News

TipRanks 12h

Sarepta presents new preclinical data at 22nd Meeting of OTS on SRP-1003

Sarepta (SRPT) Therapeutics presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society, OTS, demonstrating that SRP-1...

Simply Wall St 6d

How Investors May Respond To Sarepta Therapeutics Wider ELEVIDYS Benefit Data - Simply Wall Street

...

Simply Wall St 7d

Sarepta Therapeutics ELEVIDYS Data Puts Its Valuation Story Back In Focus

Advertisement New ELEVIDYS data reshapes the Sarepta Therapeutics story Sarepta Therapeutics (SRPT) just presented new ELEVIDYS gene therapy data to specialis...

Analyst ratings

50%

of 24 ratings

Buy

29.2%

Hold

50%

Sell

20.8%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.